[8-K] CHAMPIONS ONCOLOGY, INC. Reports Material Event

Rhea-AI Filing Summary

Champions Oncology (CSBR) reported results from its October 16, 2025 Annual Meeting. All seven director nominees were elected for one-year terms. The strongest director support was for Scott R. Tobin with 9,722,734 votes for.

Stockholders ratified the appointment of EisnerAmper LLP as independent auditor with 10,659,115 votes for. The non-binding advisory vote on executive compensation was approved with 9,720,681 votes for. Broker non-votes totaled 931,779 for proposals requiring them.

0000771856false00007718562025-10-162025-10-16

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 16, 2025

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-11504

52-1401755

(State or Other Jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

Identification No.)

1 University Plaza, Suite 307, Hackensack, New Jersey 07601

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (201) 808-8400

N/A

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

CSBR

The Nasdaq Stock Market LLC

    

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5.07. Submission of Matters to a Vote of Security Holders.

On October 16, 2025, Champions Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows:

1. Election of Directors. The seven director nominees named in the Company's 2025 proxy statement were elected to serve for a one-year term expiring at the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes:

Director Nominee						Votes For						Votes Withheld						Broker Non-Vote
Ronnie Morris, M.D.						8,992,111						735,954						931,779
Joel Ackerman						8,991,092						736,973						931,779
Robert Brainin						8,894,744						833,321						931,779
David Sidransky, M.D.						8,703,235						1,024,830						931,779
Daniel Mendelson						9,240,584						487,481						931,779
Scott R. Tobin						9,722,734						5,331						931,779
Philip Breitfeld, MD.						9,722,113						5,952						931,779

2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2026, was ratified as follows:

Votes For						Votes Against						Abstain
10,659,115						729						—

3. Non-binding Advisory Resolution Relating to the Compensation of the Company’s Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2025 proxy statement, was approved by the following votes:

Votes For						Votes Against						Abstain						Broker Non-Vote
9,720,681						7,262						122						931,779

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						CHAMPIONS ONCOLOGY, INC.
						(Registrant)
Date: October 16, 2025			By:			/s/ David Miller
						David Miller
						Chief Financial Officer

FAQ

What did CSBR stockholders approve at the 2025 Annual Meeting?

All seven directors were elected, the auditor EisnerAmper LLP was ratified with 10,659,115 votes for, and say-on-pay passed with 9,720,681 votes for.

Which CSBR director received the most votes?

Scott R. Tobin received 9,722,734 votes for.

How did the say-on-pay vote turn out for CSBR?

The advisory vote on executive compensation was approved with 9,720,681 votes for, 7,262 against, and 122 abstentions, plus 931,779 broker non-votes.

Who is CSBR’s auditor for the fiscal year ending April 30, 2026?

Stockholders ratified EisnerAmper LLP as the independent registered public accounting firm with 10,659,115 votes for and 729 against.

When was the CSBR Annual Meeting held?

The meeting was held on October 16, 2025.

What is CSBR’s trading symbol and exchange?

CSBR trades on The Nasdaq Stock Market LLC under the symbol CSBR.